Global API regulatory compliance, and what global API players must prepare for next
As global API manufacturers navigate an increasingly complex regulatory landscape, the old binaries of harmonization versus divergence no longer quite fit. Expectations appear aligned at the surface, yet inspections often reveal subtle and sometimes critical differences in interpretation, enforcement, and regulatory philosophy. To unpack what this really means for global API players, we spoke with Dr Nandkumar Patil, Vice President and Head of Regulatory Affairs at RK Pharma INC. Drawing from decades of hands-on experience across global inspections and regulatory engagements, Mr. Patil offers a clear eyed practitioner’s perspective on where regulators are truly converging, where fragmentation persists, and how API manufacturers must recalibrate their compliance strategies to remain inspection resilient, scientifically credible, and globally defensible.
Regulatory expectations today appear to be both aligning and diverging at the same time. From your vantage point, where are global regulators truly converging, and where are the fault lines beginning to show?
At a foundational level, global regulators are clearly converging on core GMP principles: data integrity, quality systems robustness, lifecycle management, and patient centric risk thinking. Initiatives such as ICH Q9 (R1) on Quality Risk Management and ICH Q12 on lifecycle management have provided a common philosophical backbone across agencies including the US FDA, EMA, PMDA, and increasingly, emerging regulators.
However, the fault lines are visible in interpretation and enforcement. While the intent may be harmonized, the inspection lens differs. For example, the FDA continues to emphasize data governance and investigator level accountability, whereas EU authorities often focus more deeply on procedural compliance and QMS documentation maturity. China’s NMPA and India’s CDSCO, meanwhile, are rapidly tightening expectations but applying them through regionally contextualized frameworks.
Global regulators are converging on what “good science and quality” look like, but diverging on how much evidence is enough and how it must be presented. For industry, this means success no longer comes from minimum compliance, but from anticipating the most stringent expectations and building globally defensible CMC strategies from the outset.
In short, convergence exists at the “what,” but fragmentation persists at the “how,” and that distinction matters greatly on the shop floor.
API manufacturers often prepare for the strictest regulator in the room. Is this still a viable strategy, or are region-specific regulatory nuances becoming too significant to ignore?
Preparing for the “strictest regulator” remains a necessary but insufficient strategy. It helps establish a high baseline, but it does not guarantee regulatory success across markets.
For instance, compliance built solely around FDA expectations may still fall short during EU inspections where EU GMP Annex 1 interpretations, QP oversight, and supplier qualification depth are scrutinized differently. Similarly, Japan’s PMDA places exceptional emphasis on procedural adherence and training effectiveness, sometimes more than western counterparts.
The data is instructive. A review of recent warning letters and inspection outcomes shows that many deficiencies are not about GMP absence, but GMP misalignment.
Therefore, global API players must evolve from a “one size fits all” compliance mindset to a globally harmonized yet locally intelligent regulatory strategy.
Data integrity observations continue to feature prominently across inspections worldwide. Do you see this as a maturity issue within organizations, or a sign that regulatory expectations themselves are evolving faster than industry adaptation?
It is, candidly, both, but predominantly a maturity issue.
Regulatory expectations around data integrity have been remarkably consistent for nearly a decade. ALCOA principles were never new. What is new is the regulatory intolerance for cultural shortcuts. Many organizations still treat data integrity as a technical problem solvable by software upgrades rather than a behavioral and governance challenge.
Inspection data from the US FDA and MHRA consistently shows that over 60 percent of data integrity observations are linked to human practices, not system limitations. This suggests that while regulations have evolved incrementally, organizational mindsets have lagged.
In other words, regulators did not suddenly move the goalpost. The industry simply stopped running while admiring the stadium.
As APIs increasingly serve multiple markets from the same site, how should companies think about inspection readiness when regulatory philosophies and inspection styles differ across geographies?
Inspection readiness must shift from an event based exercise to a continuous state of control.
Companies should design systems that are inspection agnostic but inspection resilient, where data traceability, deviation handling, and decision rationales are defensible regardless of the regulator’s inspection style. This requires strong site level governance, empowered quality leadership, and rehearsed cross functional narratives.
Equally important is inspection intelligence: understanding how different agencies inspect, what they prioritize, and how they ask questions. A US FDA inspection is often forensic and data driven, while an EU inspection may be more systemic and procedural. Preparing teams to adapt communication styles without compromising truth is now a core competency.
There is a growing perception that compliance is becoming more interpretative than prescriptive. How should global API players build internal decision making frameworks to operate confidently in this environment?
This shift from prescriptive to interpretative compliance is real and irreversible.
To navigate it, organizations must invest in principle based decision frameworks anchored in ICH guidelines, scientific rationale, and documented risk assessments. Decisions should clearly answer three questions:
- What risk are we managing?
- Why is this control appropriate?
- How is the decision justified and reviewed?
Companies that rely solely on SOPs without cultivating regulatory thinking capability will struggle. Those that embed structured risk assessments, escalation mechanisms, and independent quality challenge will operate with confidence even in grey zones.
In interpretative compliance, silence is suspicious, but rationale is respected.
Looking ahead, what regulatory shifts or inspection trends should API manufacturers start preparing for now, even if they are not yet formally codified in guidelines?
Several trends are already visible beneath the regulatory surface:
- Enhanced scrutiny of supplier ecosystems, including solvent manufacturers, intermediates, and contract labs
- Digital data governance expectations, particularly around audit trails, metadata, and cybersecurity
- Lifecycle GMP accountability, where changes, even minor ones, are expected to be proactively assessed and justified
- ESG linked compliance, with environmental controls and waste management increasingly intersecting with GMP inspections
Most notably, regulators are moving from asking “Are you compliant?” to “Can you explain why this makes sense?” API manufacturers that invest early in scientific justification, governance maturity, and compliance culture will not merely survive this transition, they will lead it.
The future of global API regulation is neither full convergence nor complete fragmentation. It is a demanding middle path where harmonized principles meet localized interpretation. Those who recognize this early will spend less time reacting to inspections and more time shaping regulatory trust.
And in today’s regulatory climate, trust, like data integrity, is non negotiable.
To hear these leaders speak directly on the insights, realities, and evolving trends shaping API manufacturing, readers can engage with the discussion live at API Connect 2026, organised by Ki Eventz, on 22 January 2026 at The Belvedere Golf & Country Club, Ahmedabad.
Disclaimer: The views and opinions expressed in this editorial are those of the interviewees and are based on their professional experience in pharmaceutical engineering and sterile manufacturing. They do not necessarily reflect the official views, policies, or positions of Hello Pharma, its management, or its affiliates. Hello Pharma does not endorse or take responsibility for any specific technical, commercial, or regulatory interpretations presented in this article. Readers are encouraged to independently evaluate the information shared, review applicable regulatory guidance, and rely on their own experience, expertise, and professional judgment before making decisions related to equipment selection, system design, validation strategy, or regulatory compliance.
